Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ACRS vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–4 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: ACRS 2 – 3 ATYR (1 Tie) Matrix Metrics: ACRS 4 – 3 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ACRS carries a Unified Composite Score of 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ACRS currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1412.4% operating margin) and revenue trajectory (+0.0% vs. -55.1% YoY).
  • Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACRS vs ATYR
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.38
-6.1% 1D
Market Cap $621.8M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.55β · 73% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $3.86 · SMA50: $4.33
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (ACRS 2 – 3 ATYR)

Columns: Metric · ACRS · ATYR
1. Valuation Multiples ACRS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 97.1x N/M
2. Growth & Scale ACRS
Revenue Growth (YoY) -55.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.4M N/A
Market Cap $621.8M $15.6M
3. Profitability & Quality ATYR
Gross Margin N/A N/A
Operating Margin -1412.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.5% -93.7%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) -$75M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.11 Book/Sh · -55.5% ROE $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 60.7% (1st %ile) 154.5% (36th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACRS (4) vs ATYR (3)
Institutional Metric ACRS ATYR Criterion Row Edge
Market Capitalization
Scale
$621.8M $15.6M Larger Scale ACRS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-55.1% +0.0% Higher Growth ATYR
Operating Margin (TTM)
Profitability
-1412.4% 0.0% Higher Margin ATYR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.5% -93.7% Higher ROE ACRS
52-Week Range Position
Momentum
26% ($2–$7) 62% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
1.55β · 73% Vol -9.67β · 13806% Vol Lower Realized Risk ACRS
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite ACRS
Trailing 12M Revenue (USD)
Operating Scale
$6.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 97.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($1.11 Book/Sh · -55.5% ROE) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2791.49 pp
ACRS: -2.73% · ATYR: +2788.76%
3M Horizon ATYR +878.37 pp
ACRS: -47.44% · ATYR: +830.93%
6M Horizon ATYR +950.85 pp
ACRS: -23.93% · ATYR: +926.92%
1Y Horizon ATYR +524.37 pp
ACRS: +34.33% · ATYR: +558.7%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACRS Revenue ATYR Revenue ACRS Op. Margin ATYR Op. Margin Margin Leader
FY2018 $10M N/A -1378.3% N/A ACRS
FY2019 $0M $0M -2627.3% -5445.0% ACRS
FY2020 $10M $10M -785.4% -152.2% ATYR
FY2021 $10M N/A -1327.1% N/A ACRS
FY2022 $30M $10M -302.0% -446.8% ACRS
FY2023 $30M $0M -311.6% -15557.8% ACRS
FY2024 $20M $0M -758.2% -28899.6% ACRS
FY2025 $10M $0M -975.9% -40856.3% ACRS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACRS BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $621.8M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACRS vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ACRS carries a Unified Composite Score of 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ACRS currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1412.4% operating margin) and revenue trajectory (+0.0% vs. -55.1% YoY). Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACRS leads the Growth & Scale pillar: ACRS posts -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACRS cumulative revenue shifted +0.0% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ACRS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

ACRS screens cheaper on headline valuation multiples. ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 97.1x EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACRS (-55.5% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 73% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.